National Cancer Center Team First in the World to Establish Method for Measuring NGS Diagnostic Errors
Development of an Analytical Method to Simultaneously Detect False Positives and False Negatives
A new path has opened to dramatically reduce next-generation sequencing (NGS) diagnostic errors that can lead to inappropriate anticancer drugs being administered to cancer patients or cause them to miss treatment opportunities.
On the 19th, the research team led by Dr. Hong Kyungman of the Division of Cancer Molecular Biology Research at the National Cancer Center announced that it has developed, for the first time in the world, an analytical technique that simultaneously measures both false-negative and false-positive errors in NGS testing. By quantitatively measuring testing errors that had remained a blind spot in the NGS diagnostic field, this new method makes it possible to select the optimal analysis kit and identify the optimal analysis conditions.
Dr. Hong Kyungman, Department of Cancer Molecular Biology, National Cancer Center. National Cancer Center
View original imageNGS is a core technology of precision medicine that analyzes gene mutations within cancer tissue to select the most suitable anticancer drugs for each patient. However, concerns have been continuously raised about the risk of false-negative errors, in which existing variants are missed, and false-positive errors, in which non-existent variants are detected, depending on the type of testing equipment, the type of kit used, and the level of expertise of the analysis personnel.
Such errors can deprive patients of necessary treatment opportunities or trigger unnecessary overtreatment, thereby threatening patient safety, and so there has been a steady demand for the establishment of sophisticated error measurement criteria. However, up to now, even in Korea, including the Ministry of Food and Drug Safety, as well as in the United States and Europe, no standardized criteria have been established to precisely measure NGS testing errors, which has posed a major limitation in managing test accuracy.
To address this problem, the research team designed an error measurement model using homozygous cells (for example, hydatidiform mole cells) whose two pairs of DNA bases are identical. They prepared standard samples by mixing homozygous DNA and ordinary heterozygous DNA in various ratios, then commissioned multiple NGS testing institutions at home and abroad that hold official accreditation to generate raw data using several targeted NGS kits.
The collected data were then analyzed through the bioinformatics analysis pipelines in use at each institution, and the resulting error patterns were compared. In addition, by cross-analyzing the results obtained using representative analysis algorithms widely used in current research settings and the latest commercial analysis software, the team quantitatively evaluated differences in the frequency of false-negative and false-positive occurrences.
The study found that, depending on the kit and analysis method, the sensitivity of mutation detection differed by up to 13.9-fold, while the frequency of false-positive errors differed by as much as 615-fold. This quantified analytical variability that had been difficult to identify using conventional approaches and is significant in that it lays the groundwork for establishing quality control standards for NGS testing.
In particular, this achievement goes beyond merely confirming technological gaps and is meaningful in that it provides concrete evidence to resolve the widely cited issue of the "lack of diagnostic standardization" in cancer diagnosis both in Korea and overseas. The research team’s analytical method is expected to offer a decisive approach for newly introducing criteria for maximum allowable false-positive and false-negative error rates in the approval processes of hospitals and testing institutions going forward.
Dr. Hong Kyungman, the principal investigator of the study, stated, "This research has significance in that it carefully examines how reliable the information provided by NGS testing is for patients in real-world clinical practice and establishes a technological foundation for precisely measuring its errors," adding, "If the analytical model defined through this study is established as a national diagnostic standard, it will provide a foundation for dramatically enhancing the completeness of precision medicine optimized for each individual cancer patient."
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
This research outcome was published in the latest issue of Genome Biology (impact factor 9.4), a leading international journal in the field of genome analysis.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.